Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters

Gene Therapy volume 8, pages 568–578 (2001)Cite this article

Abstract

In human cells, telomerase activity is regulated by transcriptional control of the telomerase reverse transcriptase gene (hTERT) whose product is the catalytic subunit of the enzyme. The hTERT promoter is active in virtually all types of tumors and immortal cells, but is silent in most adult somatic tissues. In this study, we placed the herpes simplex virus thymidine kinase gene under the control of the hTERT promoter with the aim of restricting its expression to tumor cells. In transfection experiments, the hTERT promoter driven thymidine kinase gene (hTERTp/TK) conferred ganciclovir sensitivity to all tumor and immortal cell lines tested, whereas normal somatic cells remained largely unaffected. Human hTERTp/TK-positive cancer cells implanted in nude mice developed into tumors that could be eradicated by ganciclovir treatment. The hTERTp/TK cassette was inserted into an adenovirus vector and its efficacy in reducing tumor growth was compared with that of an adenovirus carrying the thymidine kinase gene under the control of the cytomegalovirus immediate–early promoter (CMVp/TK). In a xenograft model using the human 143B osteosarcoma cell line, a single injection of either virus resulted in equivalent tumor regression and survival upon ganciclovir treatment. In animals injected intratumorally with the CMVp/TK adenovirus, expression of the thymidine kinase gene was detected in tumors, as well as in liver samples. Expression of the suicide gene in combination with ganciclovir resulted in severe liver histopathology and in an elevation of hepatic enzymes. In sharp contrast, when the hTERT promoter controlled the thymidine kinase gene, transgene expression was observed in tumors, but not in liver samples. Normal liver function in these animals was confirmed by serum levels of hepatic enzymes that were indistinguishable from those of control healthy mice. These results indicate that by restricting thymidine kinase expression to tumor cells, the hTERT promoter allows the tumoricidal effect of the suicidal gene to be exerted without detrimental consequences on healthy tissues and vital organs. The tight specificity of expression imparted by the hTERT promoter will assist the development of novel approaches to the treatment of a broad array of cancer types.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Salmons B, Saller RM, Baumann JG, Gunzburg WH . Construction of retroviral vectors for targeted delivery and expression of therapeutic genes Leukemia 1995 9: S53–S60

    PubMed  Google Scholar 

  2. Cooper MJ . Noninfectious gene transfer and expression systems for cancer gene therapy Semin Oncol 1996 23: 172–187

    CAS  PubMed  Google Scholar 

  3. Hart IR . Tissue specific promoters in targeting systemically delivered gene therapy Semin Oncol 1996 23: 154–158

    CAS  PubMed  Google Scholar 

  4. Patterson A, Harris AL . Molecular chemotherapy for breast cancer Drugs Aging 1999 14: 75–90

    Article  CAS  PubMed  Google Scholar 

  5. Miller N, Whelan J . Progress in transcriptionally targeted and regulatable vectors for genetic therapy Hum Gene Ther 1997 8: 803–815

    Article  CAS  PubMed  Google Scholar 

  6. Dachs GU, Dougherty GJ, Stratford IJ, Chaplin DJ . Targeting gene therapy to cancer: a review Oncol Res 1997 9: 313–325

    CAS  PubMed  Google Scholar 

  7. Nakamura TM et al. Telomerase catalytic subunit homologs from fission yeast and human Science 1997 277: 955–959

    Article  CAS  PubMed  Google Scholar 

  8. Meyerson M et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization Cell 1997 90: 785–795

    Article  CAS  PubMed  Google Scholar 

  9. Kilian A et al. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types Hum Mol Genet 1997 6: 2011–2019

    Article  CAS  PubMed  Google Scholar 

  10. Wright WE et al. Telomerase activity in human germline and embryonic tissues and cells Dev Genet 1996 18: 173–179

    Article  CAS  PubMed  Google Scholar 

  11. Ulaner GA et al. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts Cancer Res 1998 58: 4168–4172

    CAS  PubMed  Google Scholar 

  12. Sharma HW et al. Differentiation of immortal cells inhibits telomerase activity Proc Natl Acad Sci USA 1995 92: 12343–12346

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Yamada O, Takanashi M, Ujihara M, Mizoguchi H . Down-regulation of telomerase activity is an early event of cellular differentiation without apparent telomeric DNA change Leuk Res 1998 22: 711–717

    Article  CAS  PubMed  Google Scholar 

  14. Xu D et al. Suppression of telomerase reverse transcriptase (hTERT) expression in differentiated HL-60 cells: regulatory mechanisms Br J Cancer 1999 80: 1156–1161

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kolquist KA et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues Nat Genet 1998 19: 182–186

    Article  CAS  PubMed  Google Scholar 

  16. Chiu CP et al. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow Stem Cells 1996 14: 239–248

    Article  CAS  PubMed  Google Scholar 

  17. Hohaus S et al. Telomerase activity in human hematopoietic progenitor cells Haematologica 1997 82: 262–268

    CAS  PubMed  Google Scholar 

  18. Yasumoto S et al. Telomerase activity in normal human epithelial cells Oncogene 1996 13: 433–439

    CAS  PubMed  Google Scholar 

  19. Harle-Bachor C, Boukamp P . Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes Proc Natl Acad Sci USA 1996 93: 6476–6481

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Tahara H et al. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections Oncogene 1999 18: 1561–1567

    Article  CAS  PubMed  Google Scholar 

  21. Bachor C, Bachor OA, Boukamp P . Telomerase is active in normal gastrointestinal mucosa and not up-regulated in precancerous lesions J Cancer Res Clin Oncol 1999 125: 453–460

    Article  CAS  PubMed  Google Scholar 

  22. Nakamura Y et al. Quantitative reevaluation of telomerase activity in cancerous and noncancerous gastrointestinal tissues Mol Carcinog 1999 26: 312–320

    Article  CAS  PubMed  Google Scholar 

  23. Ramirez RD, Wright WE, Shay JW, Taylor RS . Telomerase activity concentrates in the mitotically active segments of human hair follicles J Invest Dermatol 1997 108: 113–117

    Article  CAS  PubMed  Google Scholar 

  24. Hayflick L, Moorhead PS . The serial cultivation of human diploid cell strains Exp Cell Res 1961 25: 585–621

    Article  CAS  PubMed  Google Scholar 

  25. Harley CB, Futcher AB, Greider CW . Telomeres shorten during ageing of human fibroblasts Nature 1990 345: 458–460

    Article  CAS  PubMed  Google Scholar 

  26. Harley CB . Telomere loss: mitotic clock or genetic time bomb? Mutat Res 1991 256: 271–282

    Article  CAS  PubMed  Google Scholar 

  27. Kim NW et al. Specific association of human telomerase activity with immortal cells and cancer Science 1994 266: 2011–2015

    Article  CAS  PubMed  Google Scholar 

  28. Shay JW, Bacchetti S . A survey of telomerase activity in human cancer Eur J Cancer 1997 33: 787–791

    Article  CAS  PubMed  Google Scholar 

  29. Feng J et al. The RNA component of human telomerase Science 1995 269: 1236–1241

    Article  CAS  PubMed  Google Scholar 

  30. Weinrich SL et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT Nat Genet 1997 17: 498–502

    Article  CAS  PubMed  Google Scholar 

  31. Günes Ç, Lichtsteiner S, Vasserot AP, Englert C . Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1 Cancer Res 2000 60: 2116–2121

    PubMed  Google Scholar 

  32. Matthews T, Boehme R . Antiviral activity and mechanism of action of ganciclovir Rev Infect Dis 1988 10: S490–S494

    Article  CAS  PubMed  Google Scholar 

  33. Ramesh R et al. In vivo analysis of the ‘bystander effect’: a cytokine cascade Exp Hematol 1996 24: 829–838

    CAS  PubMed  Google Scholar 

  34. Devereux TR et al. DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene Cancer Res 1999 59: 6087–6090

    CAS  PubMed  Google Scholar 

  35. Kyo S et al. Estrogen activates telomerase Cancer Res 1999 59: 5917–5921

    CAS  PubMed  Google Scholar 

  36. Misiti S et al. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells Mol Cell Biol 2000 20: 3764–3771

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Wu KJ et al. Direct activation of TERT transcription by c-MYC Nat Genet 1999 21: 220–224

    Article  CAS  PubMed  Google Scholar 

  38. Greenberg RA et al. Telomerase reverse transcriptase gene is a direct target of c-myc but is not functionally equivalent in cellular transformation Oncogene 1999 18: 1219–1226

    Article  CAS  PubMed  Google Scholar 

  39. Cong YS, Wen J, Bacchetti S . The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter Hum Mol Genet 1999 8: 137–142

    Article  CAS  PubMed  Google Scholar 

  40. Takakura M et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells Cancer Res 1999 59: 551–557

    CAS  PubMed  Google Scholar 

  41. Horikawa I, Cable PL, Afshari C, Barrett JC . Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene Cancer Res 1999 59: 826–830

    CAS  PubMed  Google Scholar 

  42. Oh S et al. In vivo and in vitro analysis of Myc for differential promoter activities of the human telomerase (hTERT) gene in normal and tumor cells Biochem Biophys Res Commun 1999 263: 361–365

    Article  CAS  PubMed  Google Scholar 

  43. Kyo S et al. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT) Nucleic Acids Res 2000 28: 669–677

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Kanaya T et al. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription Clin Cancer Res 2000 6: 1239–1247

    CAS  PubMed  Google Scholar 

  45. Oh S, Song Y, Yim J, Kim TK . The Wilms’ tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene J Biol Chem 1999 274: 37473–37478

    Article  CAS  PubMed  Google Scholar 

  46. Frederiksen KS, Petri A, Abrahamsen N, Poulsen HS . Gene therapy for lung cancer Lung Cancer 1999 23: 191–207

    Article  CAS  PubMed  Google Scholar 

  47. Bussemakers MJ . Changes in gene expression and targets for therapy Eur Urol 1999 35: 408–412

    Article  CAS  PubMed  Google Scholar 

  48. Nettelbeck DM, Jerome V, Muller R . Gene therapy: designer promoters for tumour targeting Trends Genet 2000 16: 174–181

    Article  CAS  PubMed  Google Scholar 

  49. Coen DM, Irmiere AF, Jacobson JG, Kerns KM . Low levels of herpes simplex virus thymidine-thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model Virology 1989 168: 221–231

    Article  CAS  PubMed  Google Scholar 

  50. Elshami AA et al. The effect of promoter strength in adenoviral vectors containing herpes simplex virus thymidine kinase on cancer gene therapy in vitro and in vivo Cancer Gene Ther 1997 4: 213–221

    CAS  PubMed  Google Scholar 

  51. Esandi MC et al. Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene Gene Therapy 1997 4: 3–10

    Article  Google Scholar 

  52. Majumdar AS et al. Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model Cancer Gene Ther 2000 7: 1086–1099

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank B Lemos, T Winburn and S Starr for excellent assistance in animal experiments, L Cardoza and V Votin for making the adenoviral pre-stocks, and A Delpinal for some of the RT-PCR work. We are grateful to Drs C Harley, G Morin and CP Chiu for their critical reading of the manuscript and valuable suggestions.

Author information

Author notes

  1. D E Hughes

    Present address: University of Illinois at Chicago, College of Medicine, Dept of Molecular Genetics, 900 South Ashland Ave, Chicago, IL 60607, USA

  2. S P Lichtsteiner

    Present address: Pfizer Global Research and Development, La Jolla Laboratories, 4215 Sorrento Valley Blvd, San Diego, CA 92121, USA

  3. A P Vasserot

    Present address: Applied Molecular Evolution, 3520 Dunhill Street, San Diego, CA 92121, USA

Authors and Affiliations

  1. Geron Corporation, 230 Constitution Drive, Menlo Park, CA 94025, USA

    A S Majumdar, D E Hughes, S P Lichtsteiner, Z Wang, J S Lebkowski & A P Vasserot

Authors
  1. A S Majumdar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D E Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S P Lichtsteiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Z Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J S Lebkowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A P Vasserot
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Majumdar, A., Hughes, D., Lichtsteiner, S. et al. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther 8, 568–578 (2001). https://doi.org/10.1038/sj.gt.3301421

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301421

Keywords

This article is cited by

Search

Advanced search

Quick links